1800-272-662
Shopping Cart 0
countryflagAU
Login

Avicanna Inc

Healthcare CA AVCN

0.185CAD
-(-%)

Last update at 2026-03-10T19:55:00Z

Day Range

0.180.18
LowHigh

52 Week Range

0.180.39
LowHigh

Fundamentals

  • Previous Close 0.18
  • Market Cap31.81M
  • Volume7500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.24117M
  • Revenue TTM25.37M
  • Revenue Per Share TTM0.23
  • Gross Profit TTM 13.75M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -3.61800M -8.74300M -14.73529M -16.76077M -35.04930M
Minority interest - - - - 7.89M
Net income -3.61800M -8.74300M -17.21971M -16.77454M -32.86170M
Selling general administrative 12.88M 11.89M 9.61M 12.53M 15.82M
Selling and marketing expenses 3.19M 2.16M 0.38M 0.35M 0.43M
Gross profit 12.90M 6.66M 1.12M 2.83M -0.57012M
Reconciled depreciation 0.85M 0.78M 0.89M 0.89M 1.09M
Ebit -3.28374M -8.13229M -10.57903M -10.83312M -18.53365M
Ebitda -2.43000M -7.35500M -9.69169M -9.93913M -17.44666M
Depreciation and amortization 0.85M 0.78M 0.89M 0.89M 1.09M
Non operating income net other - - - - -
Operating income -4.68000M -7.93300M -10.57903M -10.83312M -18.53365M
Other operating expenses 30.14M 25.17M 14.46M 14.68M 20.56M
Interest expense 0.33M 0.61M 1.67M 0.74M 0.26M
Tax provision - - 0.00000M 0.01M -2.18760M
Interest income 0.14M 0.58M 1.51M 1.82M 3.05M
Net interest income -0.33365M -0.61026M -1.67184M -0.73806M -0.26311M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.85748M 2.48M 0.01M -2.18760M
Total revenue 25.46M 16.79M 4.05M 3.27M 1.57M
Total operating expenses 17.58M 15.04M 11.53M 14.25M 18.42M
Cost of revenue 12.56M 10.13M 2.93M 0.44M 2.14M
Total other income expense net 1.06M -0.81000M -4.15626M -5.92766M -16.51565M
Discontinued operations - - - - -
Net income from continuing ops -3.61768M -8.74300M -14.73529M -16.77454M -32.86170M
Net income applicable to common shares -3.61768M -8.74300M -14.73529M -16.77454M -32.86170M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 20.12M 21.97M 17.62M 22.30M 30.16M
Intangible assets 0.87M 1.19M 0.17M 0.30M 0.50M
Earning assets - - - - -
Other current assets - 0.47M 0.48M 0.90M 1.32M
Total liab 10.38M 14.00M 14.16M 15.39M 16.25M
Total stockholder equity 2.31M -0.11250M -0.38356M 1.15M 6.02M
Deferred long term liab - - - - -
Other current liab 0.30M 1.39M 3.84M 3.66M 4.49M
Common stock - 81.03M 74.89M 66.24M 57.47M
Capital stock 87.00M 81.03M 74.89M 66.24M 57.47M
Retained earnings -102.09016M -98.71476M -90.82924M -77.40747M -62.03624M
Other liab - - 2.35M 2.78M 3.26M
Good will 0.33M 0.33M - - 0.00000M
Other assets - - - 0.00000M 0.56M
Cash 0.45M 0.48M 1.19M 0.03M 1.27M
Cash and equivalents - - - - -
Total current liabilities 9.27M 11.97M 11.41M 12.20M 12.82M
Current deferred revenue - - - - 4.34M
Net debt - 1.33M 2.02M 1.63M 0.67M
Short term debt - 1.71M 2.81M 1.25M 1.78M
Short long term debt - 1.56M 2.66M 1.09M 1.57M
Short long term debt total - 1.80M 3.21M 1.66M 1.94M
Other stockholder equity - - 18.52M 16.47M 12.70M
Property plant equipment - - 10.39M 14.47M 21.81M
Total current assets 7.64M 8.46M 7.06M 7.35M 6.77M
Long term investments - - 0.00000M 0.18M 0.52M
Net tangible assets - - - 0.85M 5.52M
Short term investments - - - 0.00000M 1.25M
Net receivables 2.95M 2.97M 2.15M 2.34M 1.01M
Long term debt - - 0.18M 0.42M 0.00000M
Inventory 3.97M 4.54M 3.24M 4.09M 1.93M
Accounts payable 7.77M 8.87M 4.75M 7.29M 6.56M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 17.58M -2.97086M -4.15939M -2.11300M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 1.05M
Deferred long term asset charges - - - - -
Non current assets total 12.48M 13.51M 10.55M 14.95M 23.39M
Capital lease obligations 0.11M 0.25M 0.37M 0.16M 0.36M
Long term debt total - - 0.40M 0.42M 0.16M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.40257M -3.04722M 0.81M 1.25M -1.25000M
Change to liabilities - - 0.00000M 0.81M 1.38M
Total cashflows from investing activities -0.40257M -3.04722M 0.81M 0.76M -2.70711M
Net borrowings -1.83354M -0.55292M - 0.88M 4.53M
Total cash from financing activities 3.41M 3.55M 9.90M 10.06M 17.39M
Change to operating activities - - - -0.01237M -1.16698M
Net income -3.61768M -8.74300M -14.73529M -16.77454M -32.86170M
Change in cash -0.02917M -0.71684M 1.16M -1.23573M 0.82M
Begin period cash flow 0.48M 1.19M 0.03M 1.27M 0.44M
End period cash flow 0.45M 0.48M 1.19M 0.03M 1.27M
Total cash from operating activities -2.54711M -1.40422M -7.43537M -11.66302M -13.97045M
Issuance of capital stock 4.80M 2.08M 9.08M 9.09M 12.86M
Depreciation 0.85M 0.78M 0.89M 0.89M 1.09M
Other cashflows from investing activities 0.00000M -0.49497M 0.88M 1.55M -1.25000M
Dividends paid - - - - -
Change to inventory 0.57M 1.16M 0.87M -2.15865M 0.21M
Change to account receivables -0.26187M -1.24842M 0.37M -1.49918M -0.51595M
Sale purchase of stock 4.93M 3.34M 9.08M 9.18M 12.86M
Other cashflows from financing activities 0.44M 2.02M 2.23M 2.38M 4.76M
Change to netincome - - - 6.67M 17.87M
Capital expenditures 0.40M 0.56M 0.07M 0.79M 1.46M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.79039M 4.36M 1.43M -2.44901M 0.46M
Stock based compensation 1.57M 1.94M 1.04M 1.31M 3.12M
Other non cash items -0.56516M 0.26M 3.94M 5.32M 16.43M
Free cash flow -2.94968M -1.96178M -7.50215M -12.45226M -15.42757M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVCN
Avicanna Inc		 - -% 0.18 - - 0.88 7.01 0.85 -4.2593
BHC
Bausch Health Companies Inc		 0.08 1.10% 7.33 5.94 1.34 0.29 18.74 2.18 6.64
CURA
Curaleaf Holdings Inc.		 0.02 0.65% 3.08 - 138.89 1.90 2.05 1.88 11.75
CRON
Cronos Group Inc		 0.01 0.29% 3.44 23.40 32.26 10.16 0.92 1.27 -1.9458
TLRY
Tilray Inc		 -0.14 1.40% 9.83 - 1000.00 1.34 0.56 1.09 -2.299

Reports Covered

Stock Research & News

View All

Profile

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol flower for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Avicanna Inc

480 University Avenue, Toronto, ON, Canada, M5G 1V2

Key Executives

Name Title Year Born
Mr. Aras Azadian B.Econ, Mba Co-Founder, CEO & Director NA
Dr. Frantz Le Devedec Exec. VP of R&D NA
Mr. Roland Alvarez SVP of Technical Operations NA
Ms. Ivana Maric Exec. VP of Marketing NA
Dr. Carlos Enrique Maldonado Muete SVP of Clinical Devel. NA
Ms. Caitlin Johnston Sr. VP of Strategic Partnerships & Patient Access NA
Mr. Phillip Cardella C.A., CPA Chief Financial Officer NA
Ms. Ivana Maric Executive Vice President of Marketing NA
Mr. Stephen Kim Chief Legal Officer & General Counsel of Avicanna USA Inc. NA
Dr. Karolina Urban Executive Vice President of Scientific & Medical Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.